March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and ...

Savolitinib NDA accepted by the NMPA with Priority Review status and Breakthrough Therapy designation for 2L EGFRm NSCLC patients with MET amplification, in combination with TAGRISSO ® (osimertinib), ...

The umbrella company sector has long been a breeding ground for tax avoidance and employment rights challenges. After years of mounting pressure and ...

For EASI-75, 52.3% of patients in SHUTTLE's higher dose group ... global phase 3 clinical trial programme comprised of eight studies intended to establish the safety and efficacy profile of ...

DURHAM, N.C. & CAMBRIDGE, Mass. & SEOUL, South Korea, March 10, 2025--Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...

All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

The placebo-adjusted EASI-75 was 29.5% ... Safety was generally consistent with the profile seen in earlier studies, according to Amgen and Kyowa. “In totality, the rocatinlimab results validate ...

A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a placebo-controlled trial showed. Including patients who used topical rescue ...